Literature DB >> 18506387

Induction of tolerance of dopaminergic responses in man.

S Lal1, J X Thavundayil, N M K Ng Ying Kin, X Dai, G Schwartz, A Montoya.   

Abstract

Schizophrenia may reflect a sensitization of dopaminergic (DA) function. Apomorphine (Apo), a DA receptor agonist, induces both sensitization and tolerance of DA function in rodents depending on dose intervals. We investigated sensitization and tolerance to Apo in healthy male volunteers. After a period of acclimatization to the experimental setting (Day 1) subjects were assigned randomly to two groups: Group A subjects received seven injections of placebo (physiological saline) (PLA) and Group B subjects received seven injections of Apo HCl (7 microg/kg sc) under double-blind conditions at 2 h intervals commencing at 0930 hours (Day 2) after an overnight fast. Twelve hours after the seventh injection, i.e. on Day 3, after an overnight fast all subjects received an injection of Apo. Serial samples of blood commencing at 0900 hours were drawn after the first and last injection in both groups for assay of growth hormone (GH), prolactin (PRL) and cortisol by radioimmunoassay; sleepiness was measured using the Analog Sleepiness Rating Scale and yawning recorded by video recorder. The GH response in Group B (N = 8) was (a) decreased after the eighth injection of Apo compared with the first injection of Apo (P = 0.03) and (b) decreased after the eighth injection of Apo compared with the first injection of Apo in Group A (N = 10) (P = 0.001). The number of yawns in Group B was significantly decreased after the eighth injection of Apo compared with the first injection of Apo (P = 0.042). PRL, cortisol and sleepiness were not significantly different between the first and eighth injection of Apo. Sensitization was not observed in any of the measures studied. These results are compatible with induction of acute tolerance of DA-mediated GH and yawning responses. The method used provides a safe pharmacological paradigm to examine plasticity of DA mechanisms in man. Results are discussed in the context of possible therapeutic implications for schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18506387     DOI: 10.1007/s00702-008-0068-x

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  61 in total

1.  Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.

Authors:  A Colzi; K Turner; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-05       Impact factor: 10.154

2.  Locomotor activity and stereotypy in rats following repeated apomorphine treatments at 1-, 3-, or 7-day intervals.

Authors:  B A Mattingly; J E Gotsick; C Marin
Journal:  Pharmacol Biochem Behav       Date:  1988-12       Impact factor: 3.533

3.  Effect of apomorphine on growth hormone, prolactin, luteinizing hormone and follicle-stimulating hormone levels in human serum.

Authors:  S Lal; C E De la Vega; T L Sourkes; H G Friesen
Journal:  J Clin Endocrinol Metab       Date:  1973-11       Impact factor: 5.958

4.  Effects of aporphine and emetine alkaloids on central dopaminergic mechanisms in rats.

Authors:  S Lal; T L Sourkes; K Missala; G Belendiuk
Journal:  Eur J Pharmacol       Date:  1972-10       Impact factor: 4.432

Review 5.  Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient.

Authors:  S Kapur; G Remington
Journal:  Biol Psychiatry       Date:  2001-12-01       Impact factor: 13.382

6.  Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.

Authors:  A J Hughes; S Bishop; B Kleedorfer; N Turjanski; W Fernandez; A J Lees; G M Stern
Journal:  Mov Disord       Date:  1993-04       Impact factor: 10.338

Review 7.  Dopaminergic mechanisms in idiopathic and drug-induced psychoses.

Authors:  J A Lieberman; B J Kinon; A D Loebel
Journal:  Schizophr Bull       Date:  1990       Impact factor: 9.306

8.  The development of behavioral sensitization to apomorphine is blocked by MK-801.

Authors:  J P Druhan; A Jakob; J Stewart
Journal:  Eur J Pharmacol       Date:  1993-10-12       Impact factor: 4.432

Review 9.  The brain dopaminergic system. Pharmacological, behavioural and electrophysiological studies.

Authors:  B Y Glenthøj
Journal:  Dan Med Bull       Date:  1995-02

10.  Apomorphine: clinical studies on erectile impotence and yawning.

Authors:  S Lal; Y Tesfaye; J X Thavundayil; T R Thompson; M E Kiely; N P Nair; A Grassino; B Dubrovsky
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1989       Impact factor: 5.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.